Neuland Laboratories Ltd.

BSE: 524558 NSE: NEULANDLAB
Neuland Laboratories Ltd. - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L85195TG1984PLC004393 Incorporated 07 January 1984 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: NEULANDLAB · BSE: 524558 Public Limited Company pharma Nifty 500
Data last updated
Market Cap
₹24,345 Cr
NEULANDLAB · NSE
Share Price
₹19,085.00
+0.58% today
Revenue
₹2,023 Cr
FY 2025-26 · +37.0% YoY
EBITDA
₹574 Cr
Margin 28.4%
Net Profit
₹361 Cr
FY 2025-26 · +107.7% YoY
P/E (TTM)
49.5x
P/B 13.2x
ROE
21.4%
ROCE 26.4%
Debt / Equity
0.13
Interest cover 5.0x

About Neuland Laboratories Ltd.

Data last updated:

Neuland Laboratories Ltd. is a public limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 07 January 1984 and has been in existence for over 42 years.

Neuland Laboratories is part of the Nifty 500 and BSE 500 indices.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L85195TG1984PLC004393. Its GSTIN is 36AAACN9531E1ZK (Telangana). The company holds 3 GST registrations, of which 1 is active. Its shares are listed on BSE: 524558 and NSE: NEULANDLAB.

The company has an authorised share capital of ₹44 Cr and a paid-up capital of ₹12.83 Cr. It was formerly known as Neuland Laboratories Private Limited. It is led by directors including Ramamohan Rao Davuluri (Whole-Time Director) and Sucheth Rao Davuluri (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Hyderabad, Telangana.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,022.99 Cr, a growth of 37% compared to the previous year. For the same year it recorded a net profit of ₹361.12 Cr (net margin 17.9%) and EBITDA of ₹574.5 Cr (EBITDA margin 28.4%). The net worth stands at ₹1,874.47 Cr (up 22.9% YoY). Total assets are valued at ₹2,191.61 Cr (up 29.7% YoY).

The company has about 1,860 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Neuland Labs. As per MCA filings, the company has open charges of ₹1,221.88 Cr and satisfied charges of ₹2,289.23 Cr on record. Court records list 143 cases involving the company, including 118 filed by the company and 25 filed against it; 14 cases are pending. The company has 48 deals on record (39 market trades, 5 secondary share transfers, 3 rights issues); the latest was in August 2026. Its 10 peer companies in the Pharma industry (API Manufacturers) are compared by revenue, 5 larger and 5 smaller; the largest is Indoco Remedies Limited with revenue of ₹1,670.37 Cr. The company has 9 MSME Form 1 returns on record between 2019 and 2023, listing 112 overdue payments to 27 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website neulandlabs.com.

Company Details of Neuland Laboratories Ltd.
CIN L85195TG1984PLC004393
Registration Number 004393
Incorporation Date 07 January 1984
ROC Hyderabad
Listing Status Listed (BSE: 524558, NSE: NEULANDLAB)
Company Status Active
Date of Last AGM 30 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant

CIN History of Neuland Laboratories Ltd.

Neuland Laboratories has one previous CIN (Corporate Identification Number): L85195AP1984PLC004393. The current CIN is L85195TG1984PLC004393, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L85195TG1984PLC004393Current
L85195AP1984PLC004393Previous
Key People
Ramamohan Rao Davuluri Whole-Time Director Sucheth Rao Davuluri Whole-Time Director Saharsh Rao Davuluri Whole-Time Director

Recognitions & Rankings of Neuland Laboratories

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#260
Valuation
₹21,880 Cr
Stock market indices
Nifty 500 BSE 500
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    neulandlabs.com
  • Social Media
  • Registered Address
    11th Floor (5th Level) Phoenix Ivy Building Plot No. 573A – III Road No. 82 Jubilee, Hills, Hyderabad, Telangana, India – 500033
  • Industry
    Pharma, API Manufacturers
Comprehensive company report
Neuland Laboratories Ltd. - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Neuland Laboratories Ltd. report

Financials, compliance, directors, charges, ownership and filings for Neuland Laboratories Ltd. in one report.

Financials from 2015 Directors & ownership Charges & compliance

Associated Brands with Neuland Laboratories Ltd.

Neuland Laboratories operates one associated brand: Neuland Labs. Each brand links to its own profile.

BrandDescriptionWebsite
Neuland Labs
Active pharmaceutical ingredients and peptides are manufactured globally.neulandlabs.com

Business Activity of Neuland Laboratories Ltd.

The main business activity of Neuland Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of Neuland Laboratories Ltd. FY 2025-26 filings available

Neuland Laboratories Ltd. reported revenue of ₹2,022.99 Cr (up 37% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,023 Cr
+37.0% YoY
EBITDA
₹574 Cr
+77.7% YoY
Profit After Tax
₹361 Cr
+107.7% YoY
Net Worth
₹1,874 Cr
+22.9% YoY
Total Assets
₹2,192 Cr
+29.7% YoY
Total Debt
₹301 Cr
+91.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,0231,4771,5591,191951937763
Revenue growth+37.0%-5.2%+30.8%+25.3%+1.5%+22.8%-
EBITDA574323463272143147102
EBITDA margin+28.4%+21.9%+29.7%+22.8%+15.0%+15.7%+13.4%
Profit before tax48934640121682.1510552.92
Net profit36117430016465.1770.8116.08
Net profit margin+17.9%+11.8%+19.3%+13.8%+6.9%+7.6%+2.1%
EPS (₹)282.16201.63232.61126.7549.4762.5012.57
Balance sheet
Total assets2,1921,6891,3861,1331,0939811,009
Net worth1,8741,5251,283994840786710
Total debt30115795.39128241182264
Cash & bank35525911759.1020.3619.4046.98
Net working capital814614535372344259334
Cash flow
Cash from operations34731726123760.3918957.34
Cash from investing(423)(298)(150)(61.09)(95.45)(84.47)(48.60)
Cash from financing20.9824.96(69.28)(136)37.72(114)(5.48)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue642776440514293328398311
Revenue growth (YoY)+119.2%+136.4%+10.5%+65.5%-33.4%---
Other income8.4912.468.051.807.867.4659.684.33
EBITDA22330777.1315634.4951.0786.6062.22
EBITDA margin+34.7%+39.6%+17.5%+30.2%+11.8%+15.6%+21.8%+20.0%
Depreciation26.5625.0923.9222.5420.1916.8916.3016.07
Interest6.977.216.795.374.582.352.221.06
Profit before tax19828754.4712917.5839.2912849.42
Tax50.1774.8213.9032.583.6711.4926.1816.58
Net profit14821340.5796.8513.9127.8010232.84
EPS (₹)115.10165.7631.6275.4910.8321.6779.1825.60
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,0231,4771,5591,191951937763
Revenue growth+37.0%-5.2%+30.8%+25.3%+1.5%+22.8%-
EBITDA573322462271142146101
EBITDA margin+28.3%+21.8%+29.6%+22.8%+15.0%+15.6%+13.3%
Profit before tax48834540121581.7410552.51
Net profit36017330016464.9070.4815.77
Net profit margin+17.8%+11.7%+19.2%+13.8%+6.8%+7.5%+2.1%
EPS (₹)281.47201.10232.24126.4449.2562.2412.31
Balance sheet
Total assets2,1821,6821,3791,1271,0889761,005
Net worth1,8661,5181,277988836782706
Total debt30115795.39128241182264
Cash & bank35425711558.6518.9918.0845.69
Net working capital803605527365337253328
Cash flow
Cash from operations34831826023960.4118956.63
Cash from investing(424)(298)(150)(61.50)(95.53)(84.42)(48.68)
Cash from financing20.9824.96(69.28)(136)37.72(114)(5.48)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue642776440514293328398311
Revenue growth (YoY)+119.2%+136.4%+10.5%+65.5%-33.4%---
Other income8.4912.468.051.807.867.4659.684.33
Total expenses419469363359258278312250
EBITDA22330776.9315534.2950.7586.3761.34
EBITDA margin+34.7%+39.5%+17.5%+30.2%+11.7%+15.5%+21.7%+19.7%
Depreciation26.5625.0923.9222.5420.1916.8916.3016.07
Interest6.977.236.795.344.582.352.221.06
Profit before tax19828754.2712917.3838.9712848.54
Tax50.1774.5213.8632.583.6711.2526.1516.58

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue642776440514293328398311
Revenue growth (YoY)+119.2%+136.4%+10.5%+65.5%-33.4%---
Other income8.4912.468.051.807.867.4659.684.33
EBITDA22330777.1315634.4951.0786.6062.22
EBITDA margin+34.7%+39.6%+17.5%+30.2%+11.8%+15.6%+21.8%+20.0%
Depreciation26.5625.0923.9222.5420.1916.8916.3016.07
Interest6.977.216.795.374.582.352.221.06
Profit before tax19828754.4712917.5839.2912849.42
Tax50.1774.8213.9032.583.6711.4926.1816.58
Net profit14821340.5796.8513.9127.8010232.84
EPS (₹)115.10165.7631.6275.4910.8321.6779.1825.60
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,0231,4771,5591,191951937763
Revenue growth+37.0%-5.2%+30.8%+25.3%+1.5%+22.8%-
Other income30.1796.9112.549.752.0816.103.89
Total expenses1,4481,1541,096919808790661
Employee cost341272257202182150124
EBITDA574323463272143147102
EBITDA margin+28.4%+21.9%+29.7%+22.8%+15.0%+15.7%+13.4%
Depreciation91.7465.5559.7052.7849.0439.6831.28
Interest23.958.3014.0013.0713.5017.9021.57
Profit before tax48934640121682.1510552.92
Tax12586.2210152.2318.3424.7136.72
Net profit36117430016465.1770.8116.08
Net profit margin+17.9%+11.8%+19.3%+13.8%+6.9%+7.6%+2.1%
EPS (₹)282.16201.63232.61126.7549.4762.5012.57
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital12.9012.9012.9012.9012.9012.9012.90
Reserves & surplus1,8621,5121,270981828774697
Shareholders' funds (net worth)1,8741,5251,283994840786710
Minority interest0.000.000.000.000.000.000.00
Secured loans16190.7344.92122196170246
Unsecured loans14066.4150.476.9444.0712.1218.19
Total debt30115795.39128241182264
Total liabilities2,1921,6891,3861,1331,0939811,009
Assets
Gross block1,5321,2381,093973936845746
Net block1,177955824758767716653
Capital work in progress21147.6645.8940.5720.4617.2523.75
Investments1.981091.280.523.876.907.86
Inventories510386350279265248220
Sundry debtors541316374362234218190
Cash & bank balances35525911759.1020.3619.4046.98
Loans & advances76.5371.5280.3460.7957.5258.3951.27
Total current assets1,4831,032921761577543508
Total current liabilities670418386389234284174
Net working capital814614535372344259334
Total assets2,1921,6891,3861,1331,0939811,009
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash13287.5845.425.092.4411.207.94
Net cash from operating activities34731726123760.3918957.34
Net cash from investing activities(423)(298)(150)(61.09)(95.45)(84.47)(48.60)
Net cash from financing activities20.9824.96(69.28)(136)37.72(114)(5.48)
Net change in cash(55.26)44.3642.1640.322.66(8.77)3.27
Closing cash35525911759.1020.3619.4046.98
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+37.0%-5.2%+30.8%+25.3%+1.5%+22.8%-
EBITDA growth+77.7%-30.1%+70.2%+90.6%-2.9%+44.1%-
PBT growth+41.2%-13.7%+86.1%+162.6%-22.0%+99.0%+160.1%
Net income growth+107.7%-42.1%+83.0%+151.9%-8.0%+340.4%-
Revenue CAGR (3Y)+19.3%+15.8%+18.5%+16.0%+12.6%+21.1%+9.6%
EBITDA CAGR (3Y)+28.3%+31.4%+46.6%+38.7%+34.7%+42.8%-1.4%
Profitability & leverage
Net income margin+18.0%+17.6%+19.3%+13.7%+6.7%+8.6%+2.1%
Return on capital employed+26.5%+18.6%+33.0%+20.6%+9.2%+11.1%+7.6%
Return on net worth+21.4%+12.4%+26.4%+17.8%+7.9%+9.5%+2.3%
Debt / equity0.130.090.100.200.260.300.35
Long-term debt / equity0.110.060.060.100.130.120.10
Interest cover4.963.223.475.9714.4316.7130.55
Efficiency & per share
Fixed asset turnover1.461.271.511.251.071.181.13
Inventory turnover4.524.014.954.383.714.013.70
Debtors turnover4.724.294.244.004.214.604.31
EPS (₹)282.16201.63232.61126.7549.4762.5012.57
Dividend per share (₹)34.0012.0014.0010.005.005.002.00
Book value per share (₹)1,452.371,181.32993.66769.94650.88608.98549.68
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue642776440514293328398311
Revenue growth (YoY)+119.2%+136.4%+10.5%+65.5%-33.4%---
Other income8.4912.468.051.807.867.4659.684.33
Total expenses419469363359258278312250
EBITDA22330776.9315534.2950.7586.3761.34
EBITDA margin+34.7%+39.5%+17.5%+30.2%+11.7%+15.5%+21.7%+19.7%
Depreciation26.5625.0923.9222.5420.1916.8916.3016.07
Interest6.977.236.795.344.582.352.221.06
Profit before tax19828754.2712917.3838.9712848.54
Tax50.1774.5213.8632.583.6711.2526.1516.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,0231,4771,5591,191951937763
Revenue growth+37.0%-5.2%+30.8%+25.3%+1.5%+22.8%-
Other income30.1696.9112.549.752.0816.093.89
Total expenses1,4501,1551,097920809790661
Employee cost329261249195176144118
EBITDA573322462271142146101
EBITDA margin+28.3%+21.8%+29.6%+22.8%+15.0%+15.6%+13.3%
Depreciation91.7365.5459.7052.7849.0439.6831.28
Interest23.958.3014.0013.0713.4917.9021.57
Profit before tax48834540121581.7410552.51
Tax12585.9410152.0918.2024.6636.62
Net profit36017330016464.9070.4815.77
Net profit margin+17.8%+11.7%+19.2%+13.8%+6.8%+7.5%+2.1%
EPS (₹)281.47201.10232.24126.4449.2562.2412.31
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital12.9012.9012.9012.9012.9012.9012.90
Reserves & surplus1,8531,5051,264975823769693
Shareholders' funds (net worth)1,8661,5181,277988836782706
Secured loans16190.7344.92122196145246
Unsecured loans14066.4150.476.9444.0737.1818.19
Total debt30115795.39128241182264
Total liabilities2,1821,6821,3791,1271,0889761,005
Assets
Gross block1,5311,2381,093973936845746
Net block1,177955824758767716653
Capital work in progress21147.6645.8940.5720.4617.2523.75
Investments2.141091.440.684.037.058.02
Inventories510386350279265248220
Sundry debtors541316374362234218190
Cash & bank balances35425711558.6518.9918.0845.69
Loans & advances76.1371.3980.2360.6957.3558.3051.21
Total current assets1,4811,030919760576542506
Total current liabilities679425393395239288178
Net working capital803605527365337253328
Total assets2,1821,6821,3791,1271,0889761,005
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash13086.0744.963.721.129.927.44
Net cash from operating activities34831826023960.4118956.63
Net cash from investing activities(424)(298)(150)(61.50)(95.53)(84.42)(48.68)
Net cash from financing activities20.9824.96(69.28)(136)37.72(114)(5.48)
Net change in cash(55.07)44.3141.1141.242.60(8.80)2.47
Closing cash35425711558.6518.9918.0845.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+37.0%-5.2%+30.8%+25.3%+1.5%+22.8%-
EBITDA growth+77.9%-30.2%+70.3%+90.8%-2.9%+44.3%-
PBT growth+41.2%-13.8%+86.2%+163.3%-22.1%+99.9%+164.5%
Net income growth+108.1%-42.3%+83.1%+152.4%-7.9%+346.9%-
Revenue CAGR (3Y)+19.3%+15.8%+18.5%+16.0%+12.6%+21.1%+9.6%
EBITDA CAGR (3Y)+28.3%+31.4%+46.7%+38.8%+34.9%+43.1%-1.4%
Profitability & leverage
Net income margin+18.0%+17.6%+19.2%+13.7%+6.7%+8.6%+2.1%
Return on capital employed+26.5%+18.6%+33.1%+20.6%+9.2%+11.1%+7.6%
Return on net worth+21.5%+12.4%+26.5%+17.9%+7.9%+9.5%+2.3%
Debt / equity0.140.090.100.200.260.300.35
Long-term debt / equity0.110.060.060.100.130.120.10
Interest cover4.973.233.485.9814.4816.7730.73
Efficiency & per share
Fixed asset turnover1.461.271.511.251.071.181.13
Inventory turnover4.524.014.954.383.714.013.70
Debtors turnover4.724.294.244.004.214.604.31
EPS (₹)281.47201.10232.24126.4449.2562.2412.31
Dividend per share (₹)34.0012.0014.0010.005.005.002.00
Book value per share (₹)1,445.691,175.89988.88765.49647.06605.44546.26
Want more history and ratios?
You're viewing the latest exchange-filed financials for Neuland Laboratories Ltd.. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Board of Directors of Neuland Laboratories Ltd.

Neuland Laboratories has 9 current directors and 23 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Prasad Raghava Menon
Also directs: Chemplast Sanmar Limited, Data Patterns (India) Limited
Director31 Oct 20223 Years 11 MonthsCurrent
Homi Rustam Khusrokhan
Also directs: Strides Pharma Science Limited, The Anglo Scottish Education Society
Director12 Feb 20197 Years 8 MonthsCurrent
Ramamohan Rao Davuluri
Also directs: Pattancheru Enviro-Tech Limited
Whole-Time Director07 Jan 198442 Years 9 MonthsCurrent
Sucheth Rao Davuluri
Also directs: Pattancheru Enviro-Tech Limited, Rise Athletics Association
Whole-Time Director29 Jul 200323 Years 2 MonthsCurrent
Saharsh Rao DavuluriWhole-Time Director01 Jun 200917 Years 4 MonthsCurrent
Ravi Shankar Gopinath
Also directs: Thermax Limited.
Director01 Aug 20251 Years 2 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Peer Comparison of Neuland Laboratories Ltd.

Neuland Laboratories Ltd. is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Neuland Laboratories Ltd. this company₹2,022.99 Cr (FY 2026)••••••••37.0%••••Hyderabad, Telangana, India
Indoco Remedies Limited Listed₹1,670.37 Cr (FY 2025)••••••••-9.0%••••Mumbai, Maharashtra, India
Dishman Pharmaceuticals and Chemicals Limited₹1,622.59 Cr (FY 2016)••••••••-3.0%••••Ahmedabad, Gujarat, India
Viyash Scientific Limited Listed₹1,566.06 Cr (FY 2025)••••••••13.0%••••Hyderabad, Telangana, India
Impact Therapeutics Limited₹1,499.49 Cr (FY 2024)••••••••75.0%••••Mumbai, Maharashtra, India
Virchow Petrochemical Private Limited₹1,499.36 Cr (FY 2025)••••••••-7.0%••••Patancheru, Telangana, India
Viyash Life Sciences Private Limited₹1,482.68 Cr (FY 2025)••••••••9.0%••••Hyderabad, Telangana, India
Virchow Laboratories Limited₹1,479.64 Cr (FY 2025)••••••••2.0%••••Telangana, India
Teva Api India Private Limited₹1,456.07 Cr (FY 2025)••••••••7.0%••••Mumbai, Maharashtra, India
Dhanuka Laboratories Limited₹1,424.06 Cr (FY 2025)••••••••-3.0%••••Chennai, Tamil Nadu, India
Avaya Industries Limited₹1,397.41 Cr (FY 2019)••••••••19.0%••••Thane, Maharashtra, India

Peers are the five companies nearest above and the five nearest below Neuland Laboratories by revenue in the Pharma industry (API Manufacturers), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Neuland Laboratories Ltd.

Neuland Laboratories Ltd. is audited by MSKA & ASSOCIATES for the financial year 2023.

NameStatusAppointment DateCessation Date
MSKA & ASSOCIATESLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Shareholding Pattern of Neuland Laboratories Ltd.

Shareholding for the quarter ended Sep 2026: promoters hold 32.60%, foreign institutional investors hold 21.10%, domestic institutional investors hold 16.50% and retail and other public shareholders hold 29.80%.

Promoters: 32.60%DII (Domestic Institutional): 16.50%FII (Foreign Institutional): 21.10%Retail & Others: 29.80%
Sep 2026
QUARTER
32.60% Promoters
16.50% DII (Domestic Institutional)
21.10% FII (Foreign Institutional)
29.80% Retail & Others
Promoter holding - history
Now 32.60% · Sep 2026High 32.60% · Dec 2025Low 32.60% · Dec 2025
31%31.8%32.5%33.3%34%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 32.60%Mar 2026: 32.60%Jun 2026: 32.60%Sep 2026: 32.60%32.60%32.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters32.60%32.60%32.60%32.60%
Public67.40%67.40%67.40%67.40%

Charges & Borrowings of Neuland Laboratories Ltd.

Open charges
₹1,221.88 Cr
Satisfied charges
₹2,289.23 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹1,088.75 Cr
Hdfc Bank Limited₹130.00 Cr
Axis Bank Limited₹3.13 Cr
Latest charge details
DateLenderAmountStatus
22 Dec 2025Hdfc Bank Limited₹130 CrOpen
27 Nov 2023Axis Bank Limited₹2.71 CrOpen
29 Jul 2022Sbicap Trustee Company Limited₹1,088.75 CrOpen
22 Jul 2020Axis Bank Limited₹42.4 LakhOpen
18 Mar 2025Others₹190 CrSatisfied

Total charge records: 63 View all charges

Deals & Funding of Neuland Laboratories Ltd.

Neuland Laboratories Ltd. has 48 deals on record (39 market trades, 5 secondary share transfers, 3 rights issues); the latest was in August 2026.

Total deals
48
Market trades
39
Secondary share transfers
5
Rights issues
3
QIP
1

Deals on record (5 of 48)

WhenDealAmountParties
May 2023Market trade₹41.68 CrBuyer: Graviton Research Capital LLP , an individual
Seller: Graviton Research Capital LLP
May 2023Market trade₹16.44 CrBuyer: NK Securities Research Private Limited
Seller: NK Securities Research Private Limited
Nov 2020Market trade₹8.27 CrBuyer: XTX Markets LLP
Seller: XTX Markets LLP
Aug 2020Market trade₹11.67 CrBuyer: N.K.Securities, Graviton Research Capital LLP
Seller: N.K.Securities, Graviton Research Capital LLP
Jul 2020Market trade₹4.57 CrBuyer: Pathpioneer Advisors LLP
Premium access

Full deal history

All 48 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Neuland Laboratories Ltd.

Neuland Laboratories Ltd. has 9 MSME Form 1 returns on record between 2019 and 2023, listing 112 overdue payments to 27 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 27)

SupplierAmount dueDue sinceReported on
Unitop Aquacare Limited••••••••••••
Allchem Lifescience Limited••••••••••••
Sri Vyjayanthi Labs Private Limited••••••••••••
R R Innovative Private Limited••••••••••••
Diamines and Chemicals Limited••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 9 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Neuland Laboratories Ltd.

Neuland Laboratories Ltd. has a workforce of 1,860 employees as of Apr 02, 2024.

Employee count
1,860
Active EPFO establishments
2
Employee growth
1.69%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Recent Activity on Neuland Laboratories Ltd.

Neuland Laboratories Ltd. has 43 board changes on record since 1984: 27 appointments and 16 cessations. The latest: Mauricio Futran was appointed as Additional Director on 12 May 2026.

Appointed
Mauricio Futran was appointed as Additional Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 130.00 Cr with Charge ID 101213000 was registered on 22 Dec 2025.
Charges
A charge registered on 18 Mar 2025 via Charge ID 101076510 with Others was fully satisfied on 18 Nov 2025.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 1,088.75 Cr registered on 29 Jul 2022 with Charge ID 100603089 was modified on 27 Oct 2025.
Appointed
Ravi Shankar Gopinath was appointed as Director.
AGM
Neuland Laboratories Ltd. last Annual general meeting of members was held on 30 Jul 2025 as per latest MCA records.
Ceased
Nirmala Srinivasa Murthy ceased to be Director.
Filing
Neuland Laboratories Ltd. has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge with Others amounted to Rs. 190.00 Cr with Charge ID 101076510 was registered on 18 Mar 2025.
Charges
A charge registered on 26 Apr 2024 via Charge ID 100917487 with State Bank Of India was fully satisfied on 23 Aug 2024.
Ceased
Bharati Rao ceased to be Director.
Charges
A charge with State Bank Of India amounted to Rs. 95.00 Cr with Charge ID 100917487 was registered on 26 Apr 2024.

195 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Neuland Laboratories Ltd.

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Neuland Laboratories Ltd.

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Neuland Laboratories Ltd.

Neuland Laboratories has 3 GST registrations: 1 active and 2 cancelled or inactive.

Total GSTINs
3
Active
1
Cancelled / inactive
2
GSTINStateStatusRegistered on
36AAACN9531E1ZKTelanganaActive01 Jul 2017
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Neuland Laboratories Ltd.

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Related news about Neuland Laboratories Ltd.

US FDA Signals Closure Of Unit 3 Inspection For Neuland Laboratories.
14 Oct 2026 · Exchange Update
NEULANDLAB: RS. 52.94 CRORES BSE BLOCK TRADE; FOR ~ 24,624 SHARES, AT RS. 21500.00
29 Sep 2026 · Exchange Update
NEULANDLAB: Rs. 36.35 Crores NSE Block Trade; for ~ 16,535 Shares, at Rs. 21985.00
24 Sep 2026 · Exchange Update
Neuland Laboratories: To Host Meeting With Analysts And Investors On September 23
16 Sep 2026 · Exchange Update
Neuland Laboratories: Expands Peptide Production; First Commercial Unit Now Running with 7000L Reactor Capacity; More Expansion Planned to Meet Growing Customer Needs.
15 Sep 2026 · Exchange Update

Frequently Asked Questions about Neuland Laboratories Ltd.

Neuland Laboratories is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 07 January 1984 (42+ years old) and is registered under CIN L85195TG1984PLC004393. Listed on BSE: 524558 and NSE: NEULANDLAB.

Neuland Laboratories reported revenue of ₹2,022.99 Cr for FY 2025-26 (up 37% YoY) based on consolidated financials.

Neuland Laboratories has 9 current directors:

The GSTIN of Neuland Laboratories is 36AAACN9531E1ZK, registered in Telangana. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.

The CIN (Corporate Identification Number) of Neuland Laboratories is L85195TG1984PLC004393. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Neuland Laboratories is listed on both BSE (code: 524558) and NSE (symbol: NEULANDLAB).

Neuland Laboratories has 143 court cases on record: 118 filed by the company and 25 filed against it. 14 are pending. Most are in the high courts.

Neuland Laboratories was incorporated on 07 January 1984, making it 42+ years old. It is registered with the Registrar of Companies, Hyderabad.

Neuland Laboratories has 48 deals on record (39 market trades, 5 secondary share transfers, 3 rights issues); the latest was in August 2026.

The peers of Neuland Laboratories by revenue are Indoco Remedies Limited, Dishman Pharmaceuticals and Chemicals Limited, Viyash Scientific Limited, Impact Therapeutics Limited, Virchow Petrochemical Private Limited and 5 more, all in the Pharma industry (API Manufacturers).

Mauricio Futran was appointed as Additional Director on 12 May 2026. Ravi Shankar Gopinath was appointed as Director on 01 Aug 2025. Nirmala Srinivasa Murthy ceased to be Director on 07 May 2025. Neuland Laboratories has 43 board changes on record in total.

Neuland Laboratories has 9 MSME Form 1 returns on record between 2019 and 2023, listing 112 overdue payments to 27 micro and small suppliers. The latest return was filed on 28 Aug 2023.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available